Obesity Pillars
Orforglipron linked to weight loss in a trial subgroup
Orforglipron at 17.2 mg daily was associated with 13.5% average weight loss over 72 weeks, versus 0.3% with placebo.Orforglipron at 17.2 mg daily was associated with 13.5% average weight loss over 72 weeks, versus 0.3% with placebo.
Randomized trial · 260 peopleOrforglipron
Who was studied260 adults with overweight and adiposity-related complications, against placebo
What changedBody weight fell more with 17.2 mg orforglipron than placebo at Week 72: -13.5% versus -0.3%
The catchThe subgroup analysis was post hoc and lacked power for hypothesis testing